Peter Mac 科学家开发新型 CRISPR-Cas13b 方法靶向沉默致癌基因融合
New CRISPR approach targets gene fusions found in 1 in 5 cancers
Peter Mac 科学家开发出利用 CRISPR-Cas13b 精准靶向并沉默致癌基因融合的新型策略。该方法在实验室细胞模型中成功靶向包括 BCR-ABL1 在内的 9 种基因融合,展示了高度个性化治疗潜力。该研究目前处于概念验证阶段,尚未在动物或人体中测试,下一步需验证向肿瘤递送的有效性与选择性。
Peter Mac scientists have developed a way to precisely target the "unique molecular fingerprint" created when two genes become abnormally fused together, a discovery that could lead to a new way to treat a wide array of cancers.
Dr. Mohamad Fareh explains that gene fusions are a common trigger for cancer to develop in the body. They happen when DNA breaks inside a cell and it is incorrectly repaired, joining parts of two different genes together.
In a paper published in Science Advances, Fareh notes gene fusions are present in about 20% of all cancers and gene fusions are "bona fide oncogenic drivers" for 16.5% of all cancers.
For example, the gene fusion called BCR-ABL1 (a fused version of the BCR and ABL1 genes) is present in nearly all cases of the blood cancer chronic myeloid leukemia. EWSR1-FLI1 is found in more than 85% of cases of Ewing's sarcoma, a rare cancer that can develop in bone and surrounding soft tissue.
Targeting each tumor's unique fusion pattern
In the paper, Fareh, along with Dr. Wenxin Hu and colleagues, describes a novel method that can precisely target gene fusions and silence them, stopping their cancer-driving downstream effects. It could lead to a new and highly personalized way to treat a wide array of fusion-driven cancers.
"In this study, we describe a new strategy to eliminate this class of notorious cancer drivers that are implicated in many blood and solid tumors by focusing on a unique fingerprint found only in cancer cells," Fareh says.
"Importantly, the approach is highly personalized because each patient's cancer can have a slightly different fusion pattern; the therapy can be tailored to match their specific tumor."
Reprogramming CRISPR to silence gene fusions
The method uses molecular scissors, called CRISPR-Cas13, which can be programmed to recognize the point at which the two genes had become fused. BCR-ABL1 was among nine different gene fusions that were successfully targeted and silenced in this proof-of-concept research.
"Gene fusions create a unique molecular fingerprint that we can use for highly precise targeting," says Hu.
"Instead of developing a completely different technology for every cancer, we can reprogram the CRISPR system to recognize different genetic drivers in individual tumors, bringing us one step closer to personalized cancer treatment."
Delivery to tumors remains untested
The method has so far been demonstrated in laboratory cell models, and it has not yet been tested in animals or people. The next step will be to determine how effectively the CRISPR machinery can be delivered to tumors in the body, and whether it can selectively target cancer cells in more complex models.
"Our long-term vision is to develop programmable cancer medicines that can be tailored to the genetic abnormalities driving an individual tumor," says Fareh.
"This study provides an important step toward turning the genetic information we can now identify in cancers into new ways of treating them."
Publication details
Wenxin Hu (胡文欣) et al., Programmable and selective silencing of oncogenic fusion transcripts by CRISPR-Cas13b via breakpoint sequence recognition, Science Advances (2026). DOI: 10.1126/sciadv.ady0296
Journal information: Science Advances
Key medical concepts
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: New CRISPR approach targets gene fusions found in 1 in 5 cancers (2026, October 19) retrieved 19 October 2026 from https://medicalxpress.com/news/2026-10-crispr-approach-gene-fusions-cancers.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com